Pfizer & BioNTech’s mRNA Vaccine Study
BNT162b2 is an investigational mRNA vaccine being developed by Pfizer and BioNTech to help prevent COVID-19, the disease caused by the SARS-CoV-2 virus. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and evaluate whether it is safe for adults and adolescents. BNT162b2 contains a small part of the genetic code for the SARS-CoV-2 spike protein. BNT162b2 does not contain any live virus. It cannot give you SARS-CoV-2 infection, nor will you get COVID-19.
Visit ClinicalTrials.gov - NCT04368728 for additional details.
The ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine
The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.
Visit ClinicalTrials.gov - NCT04505722 for additional details.
AstraZeneca Study of AZD122
AZD1222 is an investigational vaccine being developed by AstraZeneca to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.
The vaccine is based on a weakened version of a common cold (adenovirus) virus. The adenovirus vaccine has been changed so that it can’t replicate inside your body. It presents part of the COVID-19 spike protein to the body so that an immune response can be made to it. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and how safe it is.
Visit ClinicalTrials.gov - NCT04516746 for additional details.
Fully Enrolled Studies in Follow-up
Moderna’s mRNA-1273 vaccine, The COVE Study™
The mRNA-1273 vaccine is being developed to prevent COVID-19. The purpose of this study is to test Moderna’s vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. The mRNA-1273 vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies to fight the virus. The vaccine cannot cause infection or make someone sick with COVID-19.
Visit ClinicalTrials.gov - NCT04470427 for additional details.
Monoclonal Antibody Studies
Active Studies Recruiting Volunteers
Regeneron’s 10933 and 10987 Antibodies, the REGN-COV2 Study
REGN-COV-2 is testing a combination of two antibodies called REGN10933 and REGN10987 to see whether they are able to prevent acquisition of SARS-CoV-2. This study will enroll approximately 2,000 adults in the United States who are living in the same household as a person who has recently tested positive for SARS-CoV-2. This will include about 1,700 participants who test SARS-CoV-2 negative at enrollment and about 300 participants who have a positive SARS-CoV-2 test result but do not have any COVID-19 symptoms.
The REGN10933 and REGN10987 antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The antibodies were made in a lab by the pharmaceutical company Regeneron. REGN10933 and REGN10987 cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.
Learn more about the study and the antibodies used:
Visit http://www.regeneron.com/covid19 or ClinicalTrials.gov - NCT04452318 for additional information about the study.
Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study
BLAZE-2 is testing the LY3819253 antibody. It will be enrolling staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions are:
Does the antibody prevent the acquisition of SARS-CoV-2?
Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?
The study will be conducted in the United States with up to 2,400 participants. LY3819253 is designed to bind to SARS‑CoV-2 and prevent the virus from entering healthy cells. LY3819253 was developed in a lab by the pharmaceutical company Eli Lilly. LY3819253 cannot give you SARS-CoV-2, nor will it make you sick with COVID-19.
Visit blaze2study.com or ClinicalTrials.gov - NCT04497987 for additional details. A Spanish version of the website is available at blaze2study.com/es-us. You may also call the BLAZE-2 Call Center at (800) 953-5234 or (718) 210-9713 from 9 a.m. to 5:30 p.m. Eastern Time Monday through Friday.
What Is a Clinical Study?
Interventions that have shown promise in the laboratory and then in animal models subsequently move on to research studies in people, also known as clinical studies. The COVID-19 Prevention Network (CoVPN) will be doing studies to find safe and effective vaccines and monoclonal antibodies for the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which is the virus that causes coronavirus disease 2019 (COVID-19).
These vaccines and antibodies cannot cause SARS-CoV-2 infection or COVID-19 illness. They do not contain any live or killed virus. Participants in these studies may be exposed to the virus in their everyday lives, but they will not be exposed to the virus as part of the study (known as “challenge studies.”) These are studies of preventive vaccines that we hope will keep people healthy.
PART 2 TO FOLLOW
VACCINE STUDIES -COVID 19-PART 1.
You can discuss non medical topics but connected to treating patients here
2 posts • Page 1 of 1
- Posts: 841
- Joined: 24 Mar 2013 01:28
- Full Name: Govind Mohan
- Name of Your College/Medical School: Madras Medical College
- Posts: 707
- Joined: 26 Feb 2013 09:59
- Full Name: Kannivelu Badrinath
- Name of Your College/Medical School: Madras Medical College, Madras, India
Re: VACCINE STUDIES -COVID 19-PART 1.
It is a good analysis of the way the different vaccines work. However at the moment the public have two problems. All the different vaccines are not available for them to choose from and 2, public still have no idea what they should go for.
2 posts • Page 1 of 1